# Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

> **NCT00301912** · PHASE2 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Anemia
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** busulfan
- **DRUG:** fludarabine phosphate
- **DRUG:** methotrexate
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00301912
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2002-01
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn because study never opened to accrual
- **Last updated:** 2012-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301912, "Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00301912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*